CIM
IONS icon

Chiron Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History

Chiron Investment Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,173
Closed -$120K – 153
2022
Q4 		$120K Hold
3,173
– – 0.03% 101
2022
Q3 		$140K Buy
+3,173
New +$134K 0.03% 107

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Chiron Investment Management's IONS Position: Q1 2023 in Review

Chiron Investment Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2023, closing a stake of 3,173 shares — an estimated $120K sold.

Chiron Investment Management first reported a position in IONS in Q3 2022 and held it in 2 quarters. The position peaked at $140K in Q3 2022. 313 funds tracked by Wall St. Rank hold IONS as of Q1 2023.

  • Chiron Investment Management reported no remaining Ionis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Chiron Investment Management sold 3,173 Ionis Pharmaceuticals shares in Q1 2023, an estimated $120K.
  • Chiron Investment Management first reported a position in Ionis Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Chiron Investment Management's Ionis Pharmaceuticals position peaked at $140K in Q3 2022.
  • 313 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2023.

Based on Chiron Investment Management's 13F filing for Q1 2023, filed 15 May 2023.